Extraordinary clinical response to ibrutinib in low-grade ovarian cancer guided by organoid drug testing

Low-grade serous ovarian cancer (LGSOC) typically responds poorly to standard platinum-based chemotherapy and new therapeutic approaches are needed. We describe a remarkable response to targeted therapy in a patient with platinum-resistant, advanced LGSOC who had failed standard-of-care chemotherapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Gray, Heidi J., Chatterjee, Payel, Rosati, Rachele, Appleyard, Lauren R., Durenberger, Grace J., Diaz, Robert L., Swan, Hallie A., Peretti, Danielle, Pollastro, Maddy, Ainge, Trevor, Kapeli, Katannya, Pereira, Shalini, Margossian, Astrid L., Banda, Kalyan, Goff, Barbara A., Swisher, Elizabeth M., Bernard, Brady, Kemp, Christopher J., Grandori, Carla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10195827/
https://www.ncbi.nlm.nih.gov/pubmed/37202426
http://dx.doi.org/10.1038/s41698-023-00379-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10195827/
https://www.ncbi.nlm.nih.gov/pubmed/37202426
http://dx.doi.org/10.1038/s41698-023-00379-8

Ejemplares similares